유방 생검 시장 : 제품 유형, 지침 및 용도별 - 세계 예측(2025-2030년)

The Breast Biopsy Market was valued at USD 1.00 billion in 2023, expected to reach USD 1.09 billion in 2024, and is projected to grow at a CAGR of 9.26%, to USD 1.87 billion by 2030.

The scope of the breast biopsy market encompasses diagnostic procedures to extract tissue or fluid from the breast to determine the presence of cancerous cells, vital for early detection and treatment planning. It widely applies to patients with abnormal mammograms or palpable lumps. The key end-users include hospitals, diagnostic centers, and ambulatory surgical centers. The necessity is driven by rising breast cancer incidences, growing awareness regarding early diagnosis, and increased demand for less invasive procedures. Factors influencing market growth include technological advancements in biopsy instruments such as vacuum-assisted and image-guided methods, which enhance accuracy and reduce procedural discomfort. The increasing incidence of breast cancer and government initiatives promoting early diagnosis further bolster market expansion. Current opportunities lie in emerging markets with improving healthcare infrastructure, offering a fertile ground for market penetration. Businesses could leverage innovations such as AI-assisted image analysis and more patient-friendly biopsy protocols to enhance accuracy and patient experience. Challenges include high procedural costs, patient reluctance due to surgical anxiety, and discrepancies in biopsy results leading to false positives or negatives. Navigating regulatory hurdles poses an additional challenge, as any new technology must comply with stringent safety and efficacy standards. For sustainable growth, firms should focus on developing cost-effective solutions and enhancing procedural accuracy through technological advancements. Research into less invasive techniques, improved imaging modalities, and integrating AI for predictive diagnostics could provide competitive advantages. Moreover, personalized breast cancer diagnosis tools tailored to individual genetic profiles represent a promising area for future innovation. The market is moderately competitive, with key players continuously investing in research and development to gain a competitive edge. Companies that foster collaborations with healthcare providers and invest in educating professionals and patients are likely to capture significant market share and drive future market dynamics.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Biopsy Market

The Breast Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of breast cancer worldwide
  • Government initiative for awareness and treatment of breast cancer
  • Shifting preferences for early detection and screening for breast cancer
• Market Restraints
  • High-cost and time consuming procedure
• Market Opportunities
  • Emergence of liquid biopsy and promising clinical trials
  • Increasing investments and funding for R&D of breast cancer treatment
• Market Challenges
  • Possibilities of infection associated with biopsy needles

Porter's Five Forces: A Strategic Tool for Navigating the Breast Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Biopsy Market

A detailed market share analysis in the Breast Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Biopsy Market

A strategic analysis of the Breast Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Biopsy Market, highlighting leading vendors and their innovative profiles. These include Argon Medical, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., Cook Group Incorporated, CooperSurgical, Inc., F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., FUJIFILM Corporation, GE HealthCare, Guardant Health, Halma plc, Hologic, Inc., Illumina, Inc., INRAD, Inc., Iskus Health Ltd., Johnson & Johnson Services, Inc., Leica Biosystems Nussloch GmbH, Medtronic PLC, Merit Medical Systems, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., TransMed7, LLC, and Trivitron Healthcare.

Market Segmentation & Coverage

This research report categorizes the Breast Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Assay Kits, Biopsy Needles, Biopsy Tables, Guidance Systems, Liquid Biopsy Instruments, and Localization Wires.
• Based on Type, market is studied across Liquid Breast Biopsy, Needle Breast Biopsy, and Open Surgical Breast Biopsy. The Liquid Breast Biopsy is further studied across Circulating Tumor Cells and Circulating Tumor DNA. The Needle Breast Biopsy is further studied across Core Needle Biopsy, Fine Needle Aspiration Biopsy, and Vacuum-Assisted Biopsy. The Open Surgical Breast Biopsy is further studied across Excisional and Incisional.
• Based on Guidance, market is studied across Image-Guided Biopsy and Liquid Biopsy. The Image-Guided Biopsy is further studied across Mammography-Guided Stereotactic Biopsy, MRI Guided Biopsy, and Ultrasound-Guided Biopsy. The Liquid Biopsy is further studied across Microarray-Based Biopsy, NGS-Based Biopsy, and PCR-Based Biopsy.
• Based on Application, market is studied across Early Cancer Screening, Recurrence Monitoring, Therapy Selection, and Treatment Monitoring.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of breast cancer worldwide
    • 5.1.1.2. Government initiative for awareness and treatment of breast cancer
    • 5.1.1.3. Shifting preferences for early detection and screening for breast cancer
  • 5.1.2. Restraints
    • 5.1.2.1. High-cost and time consuming procedure
  • 5.1.3. Opportunities
    • 5.1.3.1. Emergence of liquid biopsy and promising clinical trials
    • 5.1.3.2. Increasing investments and funding for R&D of breast cancer treatment
  • 5.1.4. Challenges
    • 5.1.4.1. Possibilities of infection associated with biopsy needles
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Breast Biopsy Market, by Product

• 6.1. Introduction
• 6.2. Assay Kits
• 6.3. Biopsy Needles
• 6.4. Biopsy Tables
• 6.5. Guidance Systems
• 6.6. Liquid Biopsy Instruments
• 6.7. Localization Wires

7. Breast Biopsy Market, by Type

• 7.1. Introduction
• 7.2. Liquid Breast Biopsy
  • 7.2.1. Circulating Tumor Cells
  • 7.2.2. Circulating Tumor DNA
• 7.3. Needle Breast Biopsy
  • 7.3.1. Core Needle Biopsy
  • 7.3.2. Fine Needle Aspiration Biopsy
  • 7.3.3. Vacuum-Assisted Biopsy
• 7.4. Open Surgical Breast Biopsy
  • 7.4.1. Excisional
  • 7.4.2. Incisional

8. Breast Biopsy Market, by Guidance

• 8.1. Introduction
• 8.2. Image-Guided Biopsy
  • 8.2.1. Mammography-Guided Stereotactic Biopsy
  • 8.2.2. MRI Guided Biopsy
  • 8.2.3. Ultrasound-Guided Biopsy
• 8.3. Liquid Biopsy
  • 8.3.1. Microarray-Based Biopsy
  • 8.3.2. NGS-Based Biopsy
  • 8.3.3. PCR-Based Biopsy

9. Breast Biopsy Market, by Application

• 9.1. Introduction
• 9.2. Early Cancer Screening
• 9.3. Recurrence Monitoring
• 9.4. Therapy Selection
• 9.5. Treatment Monitoring

10. Americas Breast Biopsy Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Breast Biopsy Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Breast Biopsy Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
  • 13.3.2. Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for Menarini Group's ORSERDU for the Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
  • 13.3.3. TransMed7, LLC Announces First Clinical Use of SpeedBird Breast Biopsy Devices for Commercial Launch
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Argon Medical
• 2. Becton, Dickinson, and Company
• 3. Bio-Rad Laboratories, Inc
• 4. Biocept, Inc.
• 5. Cook Group Incorporated
• 6. CooperSurgical, Inc.
• 7. F. Hoffmann-La Roche Ltd.
• 8. Fluxion Biosciences Inc.
• 9. FUJIFILM Corporation
• 10. GE HealthCare
• 11. Guardant Health
• 12. Halma plc
• 13. Hologic, Inc.
• 14. Illumina, Inc.
• 15. INRAD, Inc.
• 16. Iskus Health Ltd.
• 17. Johnson & Johnson Services, Inc.
• 18. Leica Biosystems Nussloch GmbH
• 19. Medtronic PLC
• 20. Merit Medical Systems
• 21. Siemens Healthineers
• 22. Sysmex Corporation
• 23. Thermo Fisher Scientific Inc.
• 24. TransMed7, LLC
• 25. Trivitron Healthcare